Related Experiment Video
Updated: Aug 12, 2025
LDL Cholesterol Uptake Assay Using Live Cell Imaging Analysis with Cell Health Monitoring
Published on: November 17, 2018
Pitavastatin Compared with Differential Intervention Trial by Standard Therapy on Cardiovascular Events in Patients
Chieko Hamada1, Masumi Okuda2, Yasuhiko Tomino3
1Juntendo University Faculty of Health Sciences and Nursing, Mishima, Japan.
Insights
Pitavastatin significantly reduced cardiovascular events and all-cause mortality in chronic hemodialysis patients with dyslipidemia compared to standard dietary therapy. This study highlights pitavastatin
Area of Science:
- Cardiovascular Medicine
- Nephrology
- Pharmacology
Background:
- Cardiovascular events are a leading cause of mortality in patients undergoing chronic hemodialysis.
- Dyslipidemia is prevalent in this patient population, necessitating effective management strategies.
- The comparative efficacy of statins versus standard therapy in hemodialysis patients requires further investigation.
Purpose of the Study:
- To compare the efficacy of pitavastatin versus standard dietary therapy in reducing cardiovascular events and mortality in Japanese patients with dyslipidemia on chronic hemodialysis.
Main Methods:
- A randomized controlled trial involving 848 patients with dyslipidemia on chronic hemodialysis.
- Patients were assigned to either pitavastatin administration or standard dietary therapy (control group).
- Primary outcomes included all-cause mortality and myocardial infarction; composite outcomes assessed coronary intervention, stroke, and heart failure hospitalizations.
Main Results:
- The pitavastatin group showed a significant reduction in low-density lipoprotein cholesterol levels after 12 months.
- A total of 85 deaths occurred, with 50 in the control group and 35 in the pitavastatin group.
- Adjusted analyses revealed significant differences favoring pitavastatin for primary and composite endpoints (p = 0.007 and p = 0.022, respectively).
Conclusions:
- Pitavastatin therapy is more effective than standard dietary therapy for improving clinical outcomes in patients with dyslipidemia undergoing chronic hemodialysis.
- Aggressive lipid-lowering intervention with pitavastatin demonstrates significant benefits in this high-risk population.
- These findings support the use of pitavastatin for managing dyslipidemia in chronic hemodialysis patients to reduce cardiovascular risk.
Introduction:
Statin has been reported to reduce cardiovascular events. However, the comparative efficacy of statin with standard therapy on cardiovascular events has not been sufficiently reported in patients on chronic hemodialysis. Thus, this study aimed to compare the effects of pitavastatin and standard therapy on mortality and cardiovascular events in chronic hemodialysis patients with dyslipidemia in Japan.
Methods:
Patients on chronic hemodialysis with dyslipidemia were randomized into pitavastatin-administered (pitavastatin group) or dietary therapy as standard therapy (control) group. Primary outcomes are all-cause mortality and myocardial infarction; secondary outcomes are cardiac arrest and fatal myocardial infarction. The composite outcomes included the incidence of coronary intervention, stroke, fracture, and hospitalization due to heart failure and unstable angina. The clinical outcome analyses used a logistic regression model to categorize the variables. A p value of <0.05 was considered statistically significant.
Results:
This study included 848 patients (422 in the control group and 426 in the pitavastatin group) from 79 health facilities. The mean age of the patients was 60.1±10.3 years, and the dialysis period was 7.2±7.6 years. The mean observation period was 36.5 months. The low-density lipoprotein cholesterol level was significantly lower than the baseline value in the pitavastatin group after 12 months of trial (79.8±26.1 vs. 107.8±25.5 mg/dL, p < 0.001). Moreover, the total number of deaths was 85, of which 50 occurred in the control group and 35 in the pitavastatin group. In an analysis adjusted for confounding factors due to participant attributes, there was a significant difference between the control group and the pitavastatin group in the primary and composite endpoints (p = 0.007 and p = 0.022, respectively).
Conclusion:
Our study has demonstrated that aggressive intervention with pitavastatin is more effective than the standard (dietary) therapy for improving the clinical outcomes in patients with dyslipidemia on chronic hemodialysis.
Related Concept Videos
01:20Lipid-Lowering Drugs: Statins and Miscellaneous Agents
01:25Hemodialysis I: Introduction
01:26Atherosclerosis III: Management
01:24Hemodialysis II: Procedure and Complications
01:25Hemodialysis III: Nursing Management
01:27Coronary Artery Disease V: Interprofessional Care